Pixium Vision SA
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye's photo… Read more
Pixium Vision SA (PXMVF) - Net Assets
Latest net assets as of December 2022: $-2.85 Million USD
Based on the latest financial reports, Pixium Vision SA (PXMVF) has net assets worth $-2.85 Million USD as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.38 Million) and total liabilities ($15.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.85 Million |
| % of Total Assets | -23.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | -125.1% |
| 10-Year Change | N/A |
| Growth Volatility | 66.84 |
Pixium Vision SA - Net Assets Trend (2017–2022)
This chart illustrates how Pixium Vision SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pixium Vision SA (2017–2022)
The table below shows the annual net assets of Pixium Vision SA from 2017 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-2.85 Million | -149.02% |
| 2021-12-31 | $5.81 Million | +29.64% |
| 2020-12-31 | $4.48 Million | +21.20% |
| 2019-12-31 | $3.70 Million | -67.41% |
| 2018-12-31 | $11.35 Million | -4.07% |
| 2017-12-31 | $11.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pixium Vision SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 322993400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $7.46 Million | % |
| Total Equity | $-2.85 Million | 100.00% |
Pixium Vision SA Competitors by Market Cap
The table below lists competitors of Pixium Vision SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Project Planning Service Public Company Limited
BK:PPS
|
$2.62 Million |
|
Supergas Energy Ltd
TA:SPGE
|
$2.62 Million |
|
ONE MEDIA IP GRP LS-005
F:1M9
|
$2.62 Million |
|
SEED INNOVATIONS LTD.
F:LYZ1
|
$2.62 Million |
|
HAGA S/A Indústria e Comércio
SA:HAGA3
|
$2.62 Million |
|
Atlas Global Brands Inc.
PINK:AGBIF
|
$2.61 Million |
|
Elecster Oyj A
HE:ELEAV
|
$2.61 Million |
|
M4B SA ZY 8
F:24D
|
$2.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pixium Vision SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 5,814,000 to -2,850,000, a change of -8,664,000 (-149.0%).
- Net loss of 10,312,000 reduced equity.
- New share issuances of 5,500,000 increased equity.
- Other factors decreased equity by 3,852,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.31 Million | -361.82% |
| Share Issuances | $5.50 Million | +192.98% |
| Other Changes | $-3.85 Million | -135.16% |
| Total Change | $- | -149.02% |
Book Value vs Market Value Analysis
This analysis compares Pixium Vision SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.81 | $1.50 | x |
| 2018-12-31 | $0.53 | $1.50 | x |
| 2019-12-31 | $0.15 | $1.50 | x |
| 2020-12-31 | $0.10 | $1.50 | x |
| 2021-12-31 | $0.10 | $1.50 | x |
| 2022-12-31 | $-2.06 | $1.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pixium Vision SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -515600.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-148.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -114.41% | -602.83% | 0.09x | 2.02x | $-14.73 Million |
| 2018 | -119.52% | -996.44% | 0.06x | 1.89x | $-14.71 Million |
| 2019 | -266.89% | -555.94% | 0.13x | 3.68x | $-10.25 Million |
| 2020 | -204.03% | -639.47% | 0.09x | 3.60x | $-9.60 Million |
| 2021 | -187.99% | -1266.51% | 0.04x | 3.38x | $-11.51 Million |
| 2022 | 0.00% | -515600.00% | 0.00x | 0.00x | $-10.03 Million |
Industry Comparison
This section compares Pixium Vision SA's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pixium Vision SA (PXMVF) | $-2.85 Million | -114.41% | N/A | $2.62 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |